Gastrointestinal stromal tumors (GISTs) are the most commonly diagnosed primary mesenchymal tumors of the gastrointestinal tract and 30% of GISTs are associated with a high recurrence risk or metastasis. The current risk classification criteria of the National Comprehensive Cancer Network are based on tumor size, mitotic activity and localization. Investigating additional biomarkers associated with clinical risk may aid in the diagnosis of GIST and improves prediction of patient prognosis. In the present study, the value of using the expression levels of the oncoprotein ski as a prognostic predictor for GISTs was investigated. The results demonstrated that high ski expression levels were correlated with high risk and recurrence rates and indicated poor prognosis regarding median disease-free survival. Overall, the present study suggests that ski expression levels may serve as a predictor for clinical risk and prognosis of patients with GISTs.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most commonly reported primary mesenchymal tumors of the gastrointestinal tract (1) and 30% of GISTs are highly malignant, with a high risk of abdominal and liver metastases (2) . Therefore, it is important to improve the risk prediction for patients with a GIST prior to clinical treatment, to aid in the identification of patients who may require adjuvant imatinib therapy post-surgery (3) . Patients with tumors classified as high risk have a poor prognosis and a high risk of recurrence and metastasis (4) . The current risk classification criteria of the National Comprehensive Cancer Network (NCCN) are based on tumor size, mitotic activity and primary lesion localization, whereas tumor site and gastrointestinal bleeding are independent risk factors of a poor prognosis for patients with GISTs (5, 6) . Identifying biomarkers associated with clinical risk may aid diagnosis and improve the prognostic prediction of patients with GISTs.
As an auxiliary transcriptional regulator, ski is involved in nervous system development (7) , proliferation and differentiation of hematopoietic cells (8) , muscle differentiation (9), regeneration and wound healing (10) . Furthermore, ski is overexpressed in a number of different types of cancer, including colorectal, gastric, pancreatic and lung cancer (11) (12) (13) (14) . Our previous study demonstrated that high ski expression levels in fibrosarcoma were associated with poor tumor cell differentiation and a less favorable prognosis, and that ski significantly promoted fibrosarcoma cell proliferation (data not yet published). Fibrosarcoma and GISTs are both primary mesenchymal tumors, therefore the potential value of ski expression levels as a prognostic biomarker and risk classifier in GISTs was investigated in the present study. 
Materials and methods

Increased ski expression levels are associated with a higher risk and poor prognosis in patients with gastrointestinal stromal tumors
clinical and pathological data were obtained from patient medical records. Follow-up was performed by telephone every 2 months, starting from the date of primary diagnosis after the surgery and ending at any observable relapse (local recurrence and/or distant metastasis).
Immunohistochemistry (IHC). Rabbit polyclonal ski antibody (cat. no. sc-9140; Santa Cruz Biotechnology, Inc.) was used to determine ski expression levels. Positive and negative fibrosarcoma samples from our previous study (data not yet published) were used as positive and negative controls. Formalin-fixed and paraffin-embedded (4% neutral formalin for 6-12 h at room temperature) tissues were sliced into 4-µm-thick sections. The tissues were subsequently deparaffinized and pretreated with 1 mmol/l EDTA at pH 9.0 in a high-pressure cooker for 3 min and then treated with 3% H 2 O 2 for 10 min. Subsequently, washing was performed for 3 min three times using 0.01 M PBS at room temperature, and the slides were incubated with an anti-ski antibody (1:500) Table I ). Patients were also divided into four groups based on IHC ski expression levels: 3+, 20 cases; 2+, 24 cases; 1+, 18 cases; and 0+, 19 cases; (Fig. 1) . The numbers of patients with different levels of ski expression and in each clinical risk classification are shown in Table II . Higher ski expression levels were not significantly correlated with higher GIST clinical risk and sex, age and tumor location were not correlated with ski expression levels (Fig. 2) Higher ski expression levels are correlated with higher recurrence risk of GISTs. Follow-up data from 71 patients with GISTs were collected to determine the correlation between recurrence rates and DFS with ski expression levels. These data were analyzed using the Kaplan-Meier method. Fewer patients with low ski expression levels (IHC 0 and IHC +1) had tumor recurrence at 36 months compared with patients with high ski expression levels (IHC 2+ and 3+; 21 vs. 32%, respectively). At the 80-month follow-up period, a larger number of patients with high ski expression levels had tumor recurrence compared with patients with low ski expression levels (55.3 vs. 24.2% respectively; Table III ). Kaplan-Meier curves showed that the median DFS for the high ski expression group was shorter compared with the low ski expression group (72 months vs. N/A, respectively); however, this difference was not significant (P=0.0586; Fig. 3 ).
Discussion
Tumor size and mitotic index are the two primary factors used to assess tumor risk when utilizing the risk stratification system of the National Institutes of Health consensus (15) . However, tumor location has subsequently been shown to have independent prognostic value, therefore, this factor was added into the risk stratification system and named the Miettinen-Lasota/Armed Forces Institute of Pathology classification system (16) . Tumor size, location and mitotic index are the primary pathological factors of the risk classification system recommended by the European Society of Medical Oncology and NCCN, and are currently used in GIST guidelines (16) . Additional prognostic factors have been reported for GIST, for example, activation of stem cell factor receptor (KIT) is involved in tumorigenesis of GISTs and specific KIT mutation types and loci have demonstrated prognostic value (17) . Deletions in exon 11 of the KIT gene, particularly those involving codons 557 and/or 558, are associated with higher risk of metastases and have been reported as independent adverse prognostic factors (18, 19) . Liu et al (6) reported that gastrointestinal bleeding was an independent risk factor for recurrence. Furthermore, the Japanese Kinki GIST registry group showed that pre or perioperative 'GIST rupture' was associated with a shorter median overall survival compared with patients with GISTs without 'tumor rupture' (6.4 vs. 11.9 years, respectively) (20) . However, the clinical definition of 'tumor rupture' is impractical and ambiguous, therefore it is difficult to use 'tumor rupture' as an independent prognostic factor for GIST (21) . High ski expression levels are associated with poor prognosis in a number of types of cancer, such as esophageal carcinoma (22, 23) , leukemia (24), pancreatic cancer (25, 26) and melanoma (27) . However, to the best of our knowledge, the present study is the first to demonstrate the correlations between ski expression levels and its prognostic value for GISTs. High ski expression levels were correlated with a high clinical risk of GISTs, but not correlated with sex, age or tumor location. Together, these data suggest that ski expression levels are correlated with the prognosis of patients with GIST. Follow-up data showed that patients with GISTs in the high ski expression group had higher recurrence rates compared with patients in the low ski expression group. These data suggest that patients with GISTs with high ski expression levels may have a higher risk of recurrence during the first 3 years after complete surgical resection and diagnosis of a primary localized GIST. High ski expression levels were found to be a poor prognostic factor of median DFS; however, this difference was not significant which may be due to the small patient cohort size. Therefore, the results of the present study need to be validated using larger patient cohorts before ski expression levels can be used clinically as an independent biomarker of prognosis for patients with GIST. IHC, immunohistochemistry; low, IHC score of +0 or +1; high, IHC score of +2 or +3. 
